文献速递糖尿病

1型糖尿病进展中口服葡萄糖耐量试验的血糖与C肽峰值时间

Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts.
PubMed 文献 · Diabetes Care · 2021-08-06

本研究基于DPT-1和TrialNet PTP两个自身抗体阳性亲属队列,分析口服葡萄糖耐量试验中血糖或C肽达峰时间与1型糖尿病进展的关系。结果显示,血糖峰值时间>30分钟和C肽峰值时间>60分钟者5年糖尿病进展风险更高,且C肽峰值时间的预测性强于峰值水平。

要点

  • 血糖峰值时间>30分钟与C肽峰值时间>60分钟均提示5年糖尿病进展风险升高。
  • C肽峰值时间对糖尿病进展的预测性优于C肽峰值水平。
  • 血糖和C肽峰值延迟可作为自身抗体阳性人群的进展标志物。

核心结论

  • 在DPT-1和PTP两个独立高危人群中,OGTT血糖或C肽峰值时间延迟者5年内糖尿病进展风险更高,且独立于峰值水平。
  • C肽峰值时间比C肽峰值水平更具预测性,可能作为糖尿病进展的特异性生物标志物。

研究设计与样本

  • 研究分析了DPT-1和TrialNet PTP两个队列中自身抗体阳性亲属的2小时OGTT数据。
  • 纳入706名DPT-1参与者(平均年龄13.84±9.53岁,BMI Z评分0.33±1.07,男性56.1%)和3,720名PTP参与者(年龄16.01±12.33岁,BMI Z评分0.66±1.3,男性49.7%)。
  • 采用Log-rank检验和Cox回归分析,并调整年龄、性别、种族、BMI Z评分、HOMA-胰岛素抵抗及峰值血糖/C肽水平。

主要发现

  • 在DPT-1和PTP中,血糖峰值时间>30分钟和C肽峰值时间>60分钟者5年糖尿病进展风险均更高(所有组P<0.001),调整前后一致。
  • C肽峰值时间与糖尿病发展的关联强度大于C肽峰值水平(DPT-1:χ2=25.76 vs. χ2=8.62;PTP:χ2=149.19 vs. χ2=79.98;均P<0.001)。
  • 随着时间推移,血糖和/或C肽峰值延迟的个体百分比发生变化。

临床怎么用

  • 在自身抗体阳性1型糖尿病高危亲属中,可关注OGTT血糖峰值时间>30分钟和C肽峰值时间>60分钟以识别5年内高进展风险者。
  • C肽峰值时间或可作为优于C肽峰值水平的进展预测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody-positive relatives of people with type 1 diabetes. RESEARCH DESIGN AND METHODS: We examined 2-h OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (mean ± SD age, 13.84 ± 9.53 years; BMI Z-score, 0.33 ± 1.07; 56.1% male) and 3,720 PTP participants (age, 16.01 ± 12.33 years; BMI Z-score, 0.66 ± 1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-score, HOMA-insulin resistance, and peak glucose/C-peptide levels, respectively) were performed. RESULTS: In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose >30 min and time to peak C-peptide >60 min (P < 0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: χ2 = 25.76 vs. χ2 = 8.62; PTP: χ2 = 149.19 vs. χ2 = 79.98; all P < 0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time. CONCLUSIONS: In two independent at-risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Voss MG, Cuthbertson DD, Cleves MM, et al. Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts. Diabetes Care. 2021. PMID: 34362815. doi:10.2337/dc21-0226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。